Abstract P1-07-14: Real-life analysis evaluating >1000 N0/N1mi estrogen receptor (ER)+ breast cancer patients for whom treatment decisions incorporated the 21-gene recurrence score (RS) result: Clinical outcomes with median follow up of > 9 years
Salomon M. Stemmer(Tel Aviv University), N Ben Baruch(Tel Aviv University), Debbie McCullough(Genomic Health (United States)), Georgeta Fried(Roche (Switzerland)), Lior Soussan‐Gutman(Teva Pharmaceuticals (Israel)), Nicky Liebermann(Clalit Health Services), M. Steiner(Sheba Medical Center), Shulamith Rizel(Rabin Medical Center), Cecilia Svedman(Lund University), Avital Bareket‐Samish, Tamar Peretz(Hadassah Medical Center), Bella Nisenbaum(Meir Medical Center), L Ryvo, D. Geffen(Sheba Medical Center), Ora Rosengarten(Sheba Medical Center)
Cited by 0
Related Papers
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation
|Journal of Clinical Oncology|2014|1.7k
Efficacy and safety of olaparib monotherapy in germline BRCA1 / 2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy
|Gynecologic Oncology|2015|301
Evaluation of Seropositivity Following BNT162b2 Messenger RNA Vaccination for SARS-CoV-2 in Patients Undergoing Treatment for Cancer
|JAMA Oncology|2021|291
ChIP-seq of plasma cell-free nucleosomes identifies gene expression programs of the cells of origin
|Nature Biotechnology|2021|169
LY2495655, an antimyostatin antibody, in pancreatic cancer: a randomized, phase 2 trial
|Journal of Cachexia Sarcopenia and Muscle|2018|107